A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

被引:19
作者
Hattori, Yoshihiro [1 ]
Satouchi, Miyako [1 ]
Shimada, Temiko [1 ]
Urata, Yoshiko [1 ]
Yoneda, Tsutomu [2 ]
Mori, Masahide [2 ]
Nishimura, Takashi [3 ]
Sunadome, Hironobu [3 ]
Kumagai, Toru [4 ]
Imamura, Fumio [4 ]
Fujita, Shiro [5 ]
Kaji, Reiko [5 ]
Hata, Akito [5 ]
Tachihara, Motoko [6 ]
Morita, Satoshi [7 ]
Negoro, Shunichi [8 ]
机构
[1] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo 6738558, Japan
[2] Toneyama Natl Hosp, Natl Hosp Org, Dept Thorac Oncol, Toyonaka, Osaka, Japan
[3] Kyoto Katsura Hosp, Dept Resp Med, Kyoto, Japan
[4] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Oncol, Osaka, Japan
[5] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan
[6] Kobe Univ, Grad Sch Med, Dept Resp Med, Kobe, Hyogo 657, Japan
[7] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[8] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo 6738558, Japan
关键词
Bevacizumab; Non-small-cell lung cancer; Epidermal growth factor receptor mutation; Second-line; Carboplatin; Paclitaxel; GENE-MUTATIONS; OPEN-LABEL; GEFITINIB; CHEMOTHERAPY; MULTICENTER; ERLOTINIB; TRIAL;
D O I
10.1016/j.lungcan.2014.12.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. Materials and methods: Patients with stage IIIB or IV non-squamous NSCLC harbored activating EGFR mutations that has failed 1st-line EGFR-TKI and an Eastern Cooperative Oncology Group performance status of 0 or I were included in this study. Patients received carboplatin at an area under the concentration-time curve 5 or 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg on D1. The combination therapy was repeated every 21 days for up to three to six cycles. Bevacizumab was continued until disease progression or unacceptable toxicity for patients without disease progression (PD). The primary endpoint was objective response rate (ORR). Results: Thirty-one patients were enrolled between March 2010 and January 2013, with 30 patients being eligible. ORR was 37% (90% CI; 24-52%) and disease control rate, 83% (95% CI; 66-92%). The median progression free survival (PFS) was 6.6 months (95% CI; 4.8-12.0 months) and median-overall survival, 18.2 months (95% CI; 12.0-23.4 months). The most common grade >= 3 hematologic toxicity was neutropenia (93%), and non-hematologic toxicity, febrile neutropenia (20%). There were no clinically relevant grade >= 3 bleeding events and no treatment-related deaths. Conclusion: The combination therapy of carboplatin, paclitaxel and bevacizumab did not achieve the initial treatment goal. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:136 / 140
页数:5
相关论文
共 15 条
[1]  
[Anonymous], 2014, J Clin Oncol
[2]   Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors [J].
Dong, Lei ;
Han, Zhao-feng ;
Feng, Zi-hui ;
Jia, Zhi-yang .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2014, 42 (01) :191-197
[3]   Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J].
Inoue, A. ;
Kobayashi, K. ;
Maemondo, M. ;
Sugawara, S. ;
Oizumi, S. ;
Isobe, H. ;
Gemma, A. ;
Harada, M. ;
Yoshizawa, H. ;
Kinoshita, I. ;
Fujita, Y. ;
Okinaga, S. ;
Hirano, H. ;
Yoshimori, K. ;
Harada, T. ;
Saijo, Y. ;
Hagiwara, K. ;
Morita, S. ;
Nukiwa, T. .
ANNALS OF ONCOLOGY, 2013, 24 (01) :54-59
[4]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[5]   Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].
Maemondo, Makoto ;
Inoue, Akira ;
Kobayashi, Kunihiko ;
Sugawara, Shunichi ;
Oizumi, Satoshi ;
Isobe, Hiroshi ;
Gemma, Akihiko ;
Harada, Masao ;
Yoshizawa, Hirohisa ;
Kinoshita, Ichiro ;
Fujita, Yuka ;
Okinaga, Shoji ;
Hirano, Haruto ;
Yoshimori, Kozo ;
Harada, Toshiyuki ;
Ogura, Takashi ;
Ando, Masahiro ;
Miyazawa, Hitoshi ;
Tanaka, Tomoaki ;
Saijo, Yasuo ;
Hagiwara, Koichi ;
Morita, Satoshi ;
Nukiwa, Toshihiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388
[6]  
Mitsudomi T, 2012, J CLIN ONCOL, V30
[7]   Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].
Mitsudomi, Tetsuya ;
Morita, Satoshi ;
Yatabe, Yasushi ;
Negoro, Shunichi ;
Okamoto, Isamu ;
Tsurutani, Junji ;
Seto, Takashi ;
Satouchi, Miyako ;
Tada, Hirohito ;
Hirashima, Tomonori ;
Asami, Kazuhiro ;
Katakami, Nobuyuki ;
Takada, Minoru ;
Yoshioka, Hiroshige ;
Shibata, Kazuhiko ;
Kudoh, Shinzoh ;
Shimizu, Eiji ;
Saito, Hiroshi ;
Toyooka, Shinichi ;
Nakagawa, Kazuhiko ;
Fukuoka, Masahiro .
LANCET ONCOLOGY, 2010, 11 (02) :121-128
[8]   Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].
Mok, Tony S. ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Yang, Chih-Hsin ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Sunpaweravong, Patrapim ;
Han, Baohui ;
Margono, Benjamin ;
Ichinose, Yukito ;
Nishiwaki, Yutaka ;
Ohe, Yuichiro ;
Yang, Jin-Ji ;
Chewaskulyong, Busyamas ;
Jiang, Haiyi ;
Duffield, Emma L. ;
Watkins, Claire L. ;
Armour, Alison A. ;
Fukuoka, Masahiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957
[9]   Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations [J].
Morita, Satoshi ;
Okamoto, Isamu ;
Kobayashi, Kunihiko ;
Yamazaki, Koichi ;
Asahina, Hajime ;
Inoue, Akira ;
Hagiwara, Koichi ;
Sunaga, Noriaki ;
Yanagitani, Noriko ;
Hida, Toyoaki ;
Yoshida, Kimihide ;
Hirashima, Tomonori ;
Yasumoto, Kosei ;
Sugio, Kenji ;
Mitsudomi, Tetsuya ;
Fukuoka, Masahiro ;
Nukiwa, Toshihiro .
CLINICAL CANCER RESEARCH, 2009, 15 (13) :4493-4498
[10]   Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance [J].
Naumov, George N. ;
Nilsson, Monique B. ;
Cascone, Tina ;
Briggs, Alexandra ;
Straume, Oddbjorn ;
Akslen, Lars A. ;
Lifshits, Eugene ;
Byers, Lauren Averett ;
Xu, Li ;
Wu, Hua-Kang ;
Janne, Pasi ;
Kobayashi, Susumu ;
Halmos, Balazs ;
Tenen, Daniel ;
Tang, Xi M. ;
Engelman, Jeffrey ;
Yeap, Beow ;
Folkman, Judah ;
Johnson, Bruce E. ;
Heymach, John V. .
CLINICAL CANCER RESEARCH, 2009, 15 (10) :3484-3494